Company Description
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally.
Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.
The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system.
In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing.
The company is headquartered in Toronto, Canada.
| Country | Canada |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 304 |
| CEO | Rajiv Kanishka De Silva |
Contact Details
Address: 235 Yorkland Boulevard, Suite 900 Toronto, ON M2J 4Y8 Canada | |
| Phone | 877 848 8430 |
| Website | venus.ai |
Stock Details
| Ticker Symbol | VERO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001409269 |
| CUSIP Number | 92332W105 |
| ISIN Number | US92332W2044 |
| Employer ID | 06-1681204 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Rajiv Kanishka Liyanaarchchie De Silva | Chief Executive Officer and Director |
| Dr. Hemanth Jacob Varghese CFA, Ph.D. | President and Chief Operating Officer |
| Ross J. Portaro | Executive Vice President and GM of Global Sales and Marketing |
| Domenic Della Penna | Executive Vice President and Chief Financial Officer |
| Michael Mandarello | General Counsel and Corporate Secretary |
| William H. McGrail | Executive Vice President of Technical Operations and Compliance |
| Anat Kotler | Head of Marketing and Product Management |
| Anna Georgiadis | Chief Human Resources Officer |
| Dr. Yoni Iger | Head of Scientific and Clinical Affairs |
| Joyce Morris | Head of Sales - Canada |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | 8-K | Current Report |
| Nov 1, 2024 | EFFECT | Notice of Effectiveness |
| Oct 24, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 30, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 30, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |